CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug ...
A mail-based atrial fibrillation (AF) screening programme with ECG-patch monitoring led to a modest long-term increase in AF diagnosis and anticoagulation exposure in older patients at ...
MADRID — A simple home-based screening strategy that involved wearing an ECG patch for 14 days increased the diagnosis of atrial fibrillation (AF) and associated use of anticoagulants in patients at ...
(RTTNews) - Tempus AI, Inc (TEM), Wednesday announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECF-AF, which utilizes AI to detect ...
The use of consumer smartwatches within telemonitoring boosts new diagnoses of atrial fibrillation (AF) compared with standard approaches in older patients who are at high risk for stroke, the ...
Medical Device Network on MSN
IRhythm demonstrates value in 14-day monitoring for arrhythmia recurrence
Two retrospective studies detected arrhythmias beyond 48 hours in 30% of patients post cardiac ablation and in 60% of pregnant patients.
Detailed price information for Irhythm Holdings Inc (IRTC-Q) from The Globe and Mail including charting and trades.
Use of an Apple Watch for heart rhythm monitoring was feasible and picked up more arrhythmias than a standard patch monitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results